Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome

Table 1 Changes in measured parameters during the study

Parameter	Baseline	1st mo	3rd mo	6th mo	9th mo	12th mo	P value (ANOVA)
Age (yr)	40.5 ± 5.6	-	-	-	-	-	-
Gender (male)	16	-	-	-	-	-	-
Cigarette smoking	13	13	13	12	12	11	NS
BMI (kg/m2)	31.5 ± 1.1	31.3 ± 1.0	31.4 ± 1.0	31.6 ± 1.1	31.6 ± 1.2	31.5 ± 1.2	NS
Waist circumference (cm)	110.5 ± 6.2	110.4 ± 6.0	109.9 ± 6.1	110.6 ± 6.3	110.7 ± 6.2	110.4 ± 6.2	NS
Total cholesterol	251 ± 22	226 ± 17	192 ± 16	185 ± 12	181 ± 8	179 ± 9	< 0.001
(mg/dL)
Triglycerides	187 ± 19	161 ± 20	143 ± 26	123 ± 11	121 ± 22	117 ± 18	< 0.001
(mg/dL)
HDL-cholesterol	38 ± 5	40 ± 5	42 ± 7	42 ± 4	43 ± 3	44 ± 5	< 0.001
(mg/dL)
LDL-cholesterol	180 ± 23	152 ± 15	121 ± 17	118 ± 14	114 ± 9	110 ± 11	< 0.001
(mg/dL)
Serum creatinine	0.93 ± 0.2	0.92 ± 0.2	0.94 ± 0.2	0.92 ± 0.2	0.91 ± 0.2	0.90 ± 0.2	NS
(mg/dL)
hsCRP	4.2 ± 1.3	-	-	2.7 ± 0.8	-	1.6 ± 0.5	< 0.001
(mg/L)
BUN	34 ± 8	34 ± 8	35 ± 8	34 ± 7	33 ± 6	31 ± 6	NS
(mg/dL)
SUA	5.5 ± 1.1	5.4 ± 1.0	5.2 ± 0.9	5.0 ± 0.7	4.9 ± 0.8	4.8 ± 0.9	0.016
(mg/dL)
Plasma glucose	102 ± 8	101 ± 8	96 ± 6	93 ± 7	89 ± 5	87 ± 5	< 0.001
(mg/dL)
HbA1c	5.3 ± 0.4	-	5.1 ± 0.4	5.0 ± 0.5	4.9 ± 0.3	4.8 ± 0.3	< 0.001
(%)
Metabolic	20	20	18	9	0	0	< 0.001
Syndrome, n

Data are presented as mean ± SD. BMI: Body mass index; HDL: High density lipoprotein; LDL: Low density lipoprotein; NS: Not significant; BUN: Blood urea nitrogen; SUA: Serum uric acid; HbA_1c: Glycosylated haemoglobin.